Cargando…

In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer

Tumor angiogenesis and lymphangiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer (NSCLC). Bevacizumab, which is a monoclonal antibody, was the initial inhibitor of angiogenesis and lymphangiogenesis that received approval for use in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lung-Ching, Mokgautsi, Ntlotlang, Kuo, Yu-Cheng, Wu, Alexander T. H., Huang, Hsu-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376976/
https://www.ncbi.nlm.nih.gov/pubmed/37509650
http://dx.doi.org/10.3390/biomedicines11072011
_version_ 1785079402399268864
author Chen, Lung-Ching
Mokgautsi, Ntlotlang
Kuo, Yu-Cheng
Wu, Alexander T. H.
Huang, Hsu-Shan
author_facet Chen, Lung-Ching
Mokgautsi, Ntlotlang
Kuo, Yu-Cheng
Wu, Alexander T. H.
Huang, Hsu-Shan
author_sort Chen, Lung-Ching
collection PubMed
description Tumor angiogenesis and lymphangiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer (NSCLC). Bevacizumab, which is a monoclonal antibody, was the initial inhibitor of angiogenesis and lymphangiogenesis that received approval for use in the treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. Despite its usage, patients may still develop resistance to the treatment, which can be attributed to various histological subtypes and the initiation of treatment at advanced stages of cancer. Due to their better specificity, selectivity, and safety compared to chemotherapy, small molecules have been approved for treating advanced NSCLC. Based on the development of multiple small-molecule antiangiogenic drugs either in house and abroad or in other laboratories to treat NSCLC, we used a quinoline-derived small molecule—HN-N07—as a potential target drug for NSCLC. Accordingly, we used computational simulation tools and evaluated the drug-likeness properties of HN-N07. Moreover, we identified target genes, resulting in the discovery of the target BIRC5/HIF1A/FLT4 pro-angiogenic genes. Furthermore, we used in silico molecular docking analysis to determine whether HN-N07 could potentially inhibit BIRC5/HIF1A/FLT4. Interestingly, the results of docking HN-N07 with the BIRC5, FLT4, and HIF1A oncogenes revealed unique binding affinities, which were significantly higher than those of standard inhibitors. In summary, these results indicate that HN-N07 shows promise as a potential inhibitor of oncogenic signaling pathways in NSCLC. Ongoing studies that involve in vitro experiments and in vivo investigations using tumor-bearing mice are in progress, aiming to evaluate the therapeutic effectiveness of the HN-N07 small molecule.
format Online
Article
Text
id pubmed-10376976
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103769762023-07-29 In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer Chen, Lung-Ching Mokgautsi, Ntlotlang Kuo, Yu-Cheng Wu, Alexander T. H. Huang, Hsu-Shan Biomedicines Article Tumor angiogenesis and lymphangiogenesis pathways have been identified as important therapeutic targets in non-small cell lung cancer (NSCLC). Bevacizumab, which is a monoclonal antibody, was the initial inhibitor of angiogenesis and lymphangiogenesis that received approval for use in the treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. Despite its usage, patients may still develop resistance to the treatment, which can be attributed to various histological subtypes and the initiation of treatment at advanced stages of cancer. Due to their better specificity, selectivity, and safety compared to chemotherapy, small molecules have been approved for treating advanced NSCLC. Based on the development of multiple small-molecule antiangiogenic drugs either in house and abroad or in other laboratories to treat NSCLC, we used a quinoline-derived small molecule—HN-N07—as a potential target drug for NSCLC. Accordingly, we used computational simulation tools and evaluated the drug-likeness properties of HN-N07. Moreover, we identified target genes, resulting in the discovery of the target BIRC5/HIF1A/FLT4 pro-angiogenic genes. Furthermore, we used in silico molecular docking analysis to determine whether HN-N07 could potentially inhibit BIRC5/HIF1A/FLT4. Interestingly, the results of docking HN-N07 with the BIRC5, FLT4, and HIF1A oncogenes revealed unique binding affinities, which were significantly higher than those of standard inhibitors. In summary, these results indicate that HN-N07 shows promise as a potential inhibitor of oncogenic signaling pathways in NSCLC. Ongoing studies that involve in vitro experiments and in vivo investigations using tumor-bearing mice are in progress, aiming to evaluate the therapeutic effectiveness of the HN-N07 small molecule. MDPI 2023-07-17 /pmc/articles/PMC10376976/ /pubmed/37509650 http://dx.doi.org/10.3390/biomedicines11072011 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Lung-Ching
Mokgautsi, Ntlotlang
Kuo, Yu-Cheng
Wu, Alexander T. H.
Huang, Hsu-Shan
In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title_full In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title_fullStr In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title_full_unstemmed In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title_short In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer
title_sort in silico evaluation of hn-n07 small molecule as an inhibitor of angiogenesis and lymphangiogenesis oncogenic signatures in non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376976/
https://www.ncbi.nlm.nih.gov/pubmed/37509650
http://dx.doi.org/10.3390/biomedicines11072011
work_keys_str_mv AT chenlungching insilicoevaluationofhnn07smallmoleculeasaninhibitorofangiogenesisandlymphangiogenesisoncogenicsignaturesinnonsmallcelllungcancer
AT mokgautsintlotlang insilicoevaluationofhnn07smallmoleculeasaninhibitorofangiogenesisandlymphangiogenesisoncogenicsignaturesinnonsmallcelllungcancer
AT kuoyucheng insilicoevaluationofhnn07smallmoleculeasaninhibitorofangiogenesisandlymphangiogenesisoncogenicsignaturesinnonsmallcelllungcancer
AT wualexanderth insilicoevaluationofhnn07smallmoleculeasaninhibitorofangiogenesisandlymphangiogenesisoncogenicsignaturesinnonsmallcelllungcancer
AT huanghsushan insilicoevaluationofhnn07smallmoleculeasaninhibitorofangiogenesisandlymphangiogenesisoncogenicsignaturesinnonsmallcelllungcancer